Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
First Natural Brands is the owner of Tisserand Aromatherapy, one of the leading self-governing players in UK’s essential oil industry. It offers a variety of affordable organic and quality accredited products which consumers can relish as part of their daily lifestyle. Tisserand Aromatherapy is experiencing a growing interest among media, retail and consumers. Since 2007, the company’s sales have increased from £1.7mn to £6mn, owing to Robin Russell (CEO & Chairman) for bringing Tisserand into the mainstream market with a value for money proposition. Further investment will allow the company to expand its production capacity.
days to go:
Expired
investment:
£325,660
Occuity seeks to develop revolutionary non-invasive screening and monitoring devices for chronic diseases like diabetes and Alzheimer's. It argues that its device safely shines a low power beam of light into the eye and then collects and analyses the return signal to accurately measure structures within the eye and detect changes associated with the onset of the aforementioned diseases. Occuity is targeting three distinct markets, namely Ophthalmology, Disease Screening and Disease Monitoring, which is worth an estimated $35 billion per year. It claims that its 'Occuity Indigo' product enables earlier detection of diabetes and provides a non-contacting, pain-free glucose monitor. Occuity was awarded over £1.5 million as part of the Innovate UK grant for the development of technology within Occuity Indigo. It has also signed a partnership with one of the UK's leading ophthalmic distributors, Birmingham Optical, to distribute its PM1 pachymeter device. It states it will use 42% of the investment towards Research and Development (R&D), 23% towards sales and marketing, 20% towards management and finance, 9% towards managing CAPEX and NRE, and 6% towards paying fees.
days to go:
Expired
investment:
£2,854,857
Future You Cambridge is a company that sells clinically proven health supplements directly to consumers. Since its launch in 2016, it has sold products to over 100,000 customers. The company's Lactolycopene product received a patent in December 2017 and its Fertility+ product was also covered by the European Journal of Nutrition in a clinical paper and was shown to have resulted in a 40% increase in male fertility. The company's offerings now stand at 24 products, including the popular CBD product and its first product for pets, Curcupet-K9. Additionally, the company won the 2018 Cambridge Service Excellence and Independent High Growth Business of the Year Awards and has 5-star ratings on Trustpilot. They will use the investment to scale up direct advertising campaigns, expand its product range by more than 10 new products, and invest in their website to make it more intuitive.
days to go:
Expired
investment:
£655,011
By combining fitness with fashion, art and design, BLOK has become a major competitor of boutique class-based gyms within London. BLOK has appeared on Britain's Next Top Model, as well as working with global stars including Anthony Joshua and Jordan Dunn.
days to go:
Expired
investment:
£891,790
OXTO Energy is an energy storage technology provider that intends to transform the way energy is stored. It claims to have developed an innovative energy storage flywheel technology made using 100% recyclable steel, having a low cost of operation, and being easy to manufacture. It argues that it has secured approximately £1.7 million worth of revenues through contracts for 2021 in UK, Kenya, and France, to name a few. It also aspires to become a minority partner of large infrastructure projects by offering its units at a discounted rate, guaranteeing a consistent revenue stream while increasing profitability throughout the project. It wants to dominate the estimated £70 billion energy storage market. The company states it will use 25% of the investment to grow its team, 60% for project delivery, and 15% towards growth and commercialisation of its business.
days to go:
Expired
investment:
£635,493
Angels on the Park is a nursery opening in East London that provide flexible childcare, extended their operating hours and arrange babysitting in the family home.
(EIS pending) (SEIS Pending)
days to go:
Expired
investment:
£61,450
